BioSpace News Archive

Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies, announced that it will host a conference call on Tuesday, October 17, 2023 at 8:00 a.m. ET to discuss clinical program updates and organizational cost measures and resource prioritization to support clinical milestones.

Sutro Biopharma, Inc. announced that the company will have five presentations and one poster at the 14th Annual World ADC Conference, taking place in San Diego, October 16-19, 2023.

Ascendis Pharma A/S (Nasdaq: ASND) shared 52-week data from the open-label extension period of its ongoing Phase 3 PaTHway Trial of TransCon PTH (palopegteriparatide) showing that adults with chronic hypoparathyroidism, whose bones tend to be over-mineralized due to insufficient parathyroid hormone (PTH) exposure, trended toward a new skeletal steady state closer to age-appropriate norms with continued use of TransCon PTH.

Omnicell, Inc. (Nasdaq:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the third quarter 2023, before market open on Thursday, November 2, 2023.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced the publication of naxitamab-based chemoimmunotherapy in patients with chemoresistant high-risk neuroblastoma (“HR-NB”) in the journal Cancers.

Harpoon Therapeutics, Inc. (Nasdaq: HARP) today announced that it will host a live webcast at 8:00 a.m. ET / 2:00 p.m. CEST on Monday, October 23, 2023 to review interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN) presented at the European Society of Medical Oncology Congress (ESMO) 2023.

SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2023 after market close on Monday, November 6, 2023.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will report financial results for the third quarter of 2023 after market close on Monday, November 6, 2023.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, for the treatment of patients with resectable (tumors ≥4 centimeters [cm] or node positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.

Celltrion Healthcare today presented Phase III data from the LIBERTY-CD and LIBERTY-UC clinical trials, for the investigational subcutaneous (SC) infliximab in inflammatory bowel disease (IBD) treatment at the United European Gastroenterology (UEG) Week 2023 in Copenhagen.